The invention relates to a new biologically active chemical substance, in particular to the synthesis of a previously unknown compound of zinc (II) diacetylcysteinate with the following general formula: [Zn (CHNOS)], also called zincas, which can be used in veterinary medicine as a mucolytic drug for the treatment of animal diseases. The aim of the invention is to find a new, more effective means for the treatment of respiratory diseases. This goal is achieved by the use of a new coordination compound, zinc, zinc (II) diacetylcysteinate [Zn (CHNOS)], which is synthesized by the interaction of zinc sulfate with acetylcysteine (ACC) and has mucolytic activity. It has been established that zincas does not even cause minor effects of hyperemia, edema, scratching at the site of application. The animals also showed no signs of toxicosis with cutaneous application of the test compounds. Zincas showed no skin-irritating and skin-resorptive action.
展开▼
